HONG KONG, Nov 24, 2015 - (ACN Newswire) - Uni-Bio Science Group Limited ("Uni-Bio" or the "Group"; HKEx code: 690) today announced that it will acquire exclusive global rights to manufacture and commercialise mitiglinide, a new oral antidiabetic agent, from Jiangsu Hansoh Pharmaceutical Co.
4 Treatment with a single antidiabetic agent is often unsuccessful in achieving and /or maintaining glycemic control in patients with type 2 DM and many patients require combination of antidiabetic agents.
The PROactive Study (Prospective Pioglitazone Clinical Trial In Macrovascular Events Study) showed that ACTOS (generic name: pioglitazone HCI), an oral antidiabetic agent, can reduce the risk of developing and dying of cardiovascular diseases including heart attack and strokes in type 2 diabetics.
For example, patients with newly diagnosed, but untreated, diabetes, with no evidence of end organ damage, would be used to test a new antidiabetic agent.
5% and [less than or equal to] 10% who failed to achieve glycemic control with two oral antidiabetic drugs for [greater than or equal to] 3 months; hence a third antidiabetic agent was desirable in our patients.